Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature

Diagnostic Pathology

Svetislav Tatić⁴  Dubravka Cvejić²  Vesna Božic³  Ivan Soldatović¹  Ivan Boričic⁴  Jasmina Marković Lipkovski⁴  Duško Dunđerović⁴ 

[1] Faculty of Medicine, University of Belgrade, dr Subotica 8, Belgrade, 11000, Serbia;Institute for the application of nuclear energy, Belgrade, Serbia, Banatska 31b, Zemun, Zemun, 11080, Serbia;Department of Pathology, Centre for Endocrine Surgery, Clinic for Diabetes and Metabolic Diseases, Clinical Center of Serbia, Dr. Koste Todorovića 8, Belgrade, 11000, Serbia;Institute of Pathology, Faculty of Medicine, University of Belgrade, dr Subotica 1, Belgrade, 11000, Serbia

关键词: HBME-1;    Galectin 3;    CK19;    CD56;    Tissue Microarray;    Immunohistochemistry;    Thyroid;   

Others  :  1233596
DOI  :  10.1186/s13000-015-0428-4

 received in 2015-07-02, accepted in 2015-10-17,  发布年份 2015

【 摘 要 】

Background

Nodular follicular lesions of thyroid gland comprise benign and malignant neoplasms, as well as some forms of hyperplasia. “Follicular” refers to origin of cells and in the same time to growth pattern - building follicles. Nodular follicular thyroid lesions have in common many morphological features, therefore attempts were made to define additional criteria for distinction between follicular adenoma, follicular carcinoma and follicular variant of papillary carcinoma. Increasing number of immunohistochemical markers is in the continual process of evaluation.

Methods

Tissue microarrays incorporating, total 201 cases, out of which 122 malignant and 79 benign follicular lesions, including neoplastic and non-neoplastic, were constructed and immunostained with antibodies to CD56, CK19, Galectin-3, HBME-1. Tissue cores were exclusively being acquired from tumour/lesion on interface with normal thyroid tissue. A systematic review of literature was done for period from the year 2001 to present time.

Results

All analysed markers may make a difference between benign lesions/tumours from differentiated thyroid carcinomas (p = <0.01, for all markers). Expression of all markers is significantly higher in papillary carcinoma than in follicular adenoma (p < 0.01). Statistically significant difference in expression of Galectin-3 and CD56 between follicular carcinoma and follicular adenoma was registered (p = 0.043; p = 0.028, respectively). The only marker which expression showed statistically significant difference between adenoma and carcinoma of Hurthle cells was Galectin 3 (p = 0.041). CK19 and HBME-1 were significantly expressed more in papillary carcinoma as compared to follicular carcinoma.

Conclusion

Galectin 3 is most sensitive marker for malignancy, while loss of expression of CD56 is very specific for malignancy. Expected co-expression for combination of markers in diagnosis of follicular lesions decreases sensitivity and increases specificity for malignancy.

【 授权许可】

   
2015 Dunđerović et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Sternberg’s Diagnostic Surgical Pathology (2-Volume Set). Carter D, Greenson JK, Reuter VE, Stoler MH, Mills SE, editors: LWW; 2009; 3104 p.
• [2]Gharib H, Papini E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am. 2007; 36(3):707-35.
• [3]Murray D. In: Kovacs KaA S, ed. The thyroid gland. Malden: Blackwell Science, 1998:295–380.
• [4]Mete O, Asa SL. Pitfalls in the diagnosis of follicular epithelial proliferations of the thyroid. Adv Anat Pathol. 2012; 19(6):363-73.
• [5]Rosai J. The encapsulated follicular variant of papillary thyroid carcinoma: back to the drawing board. Endocr Pathol. 2010; 21(1):7-11.
• [6]Liu Z, Zhou G, Nakamura M, Koike E, Li Y, Ozaki T et al.. Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal. Cancer Sci. 2011; 102(1):288-94.
• [7]Boerner SL, Asa SL. Biopsy Interpretation of the Thyroid. Lippincott Williams & Wilkins, Philadelphia; 2010.
• [8]Cibas ES, Baloch ZW, Fellegara G, LiVolsi VA, Raab SS, Rosai J et al.. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med. 2013; 159(5):325-32.
• [9]Ozolins A, Narbuts Z, Strumfa I, Volanska G, Stepanovs K, Gardovskis J. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules. Medicina (Kaunas). 2012; 48(10):507-14.
• [10]Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park do J et al.. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci. 2007; 22(4):621-8.
• [11]Nechifor-Boila A, Catana R, Loghin A, Radu TG, Borda A. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Rom J Morphol Embryol. 2014; 55(1):49-56.
• [12]Kwaspen FH, Smedts FM, Broos A, Bulten H, Debie WM, Ramaekers FC. Reproducible and highly sensitive detection of the broad spectrum epithelial marker keratin 19 in routine cancer diagnosis. Histopathology. 1997; 31(6):503-16.
• [13]Sethi K, Sarkar S, Das S, Mohanty B, Mandal M. Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol. 2010; 8(4):341-52.
• [14]Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol. 2006; 17(3):225-34.
• [15]Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol. 2010; 63(9):786-9.
• [16]Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol. 2006; 126(5):700-8.
• [17]Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006; 19(12):1631-7.
• [18]Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2005; 18(1):48-57.
• [19]Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 2003; 14(1):55-60.
• [20]Erkilic S, Aydin A, Kocer NE. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Pathol. 2002; 13(3):207-11.
• [21]Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol. 2001; 116(5):696-702.
• [22]Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001; 14(4):338-42.
• [23]Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol. 2010; 21(2):80-9.
• [24]Wiseman SM, Melck A, Masoudi H, Ghaidi F, Goldstein L, Gown A et al.. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol. 2008; 15(10):2811-26.
• [25]Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol. 2008; 158(3):375-84.
• [26]Murphy KM, Chen F, Clark DP. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling. Hum Pathol. 2008; 39(3):420-6.
• [27]Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X et al.. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol. 2006; 17(3):213-23.
• [28]Rossi ED, Raffaelli M, Mule A, Miraglia A, Lombardi CP, Vecchio FM et al.. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology. 2006; 48(7):795-800.
• [29]Song Q, Wang D, Lou Y, Li C, Fang C, He X et al.. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol. 2011; 6:126. BioMed Central Full Text
• [30]Beesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002; 41(3):236-43.
• [31]de Matos PS, Ferreira AP, de Oliveira FF, Assumpcao LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005; 47(4):391-401.
• [32]Jang MH, Jung KC, Min HS. The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 delta in Follicular Thyroid Carcinoma. J Pathol Transl Med. 2015; 49(2):112-7.
• [33]Yassin FE. Diagnostic criteria of well differentiated thyroid tumor of uncertain malignant potential; a histomorphological and immunohistochemical appraisal. J Egypt Natl Canc Inst. 2015; 27:59.
• [34]Choi YL, Kim MK, Suh JW, Han J, Kim JH, Yang JH et al.. Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci. 2005; 20(5):853-9.
• [35]Abd-El Raouf SM, Ibrahim TR. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Pathol Res Pract. 2014; 210(12):971-8.
• [36]Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G et al.. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003; 88(5):2318-26.
• [37]Mai KT, Bokhary R, Yazdi HM, Thomas J, Commons AS. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes. Histopathology. 2002; 40(2):133-42.
• [38]Liang HS, Zhong YH, Luo ZJ, Huang Y, Lin HD, Luo M et al.. Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study. J Int Med Res. 2009; 37(3):927-38.
• [39]Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F et al.. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res. 2005; 25(1A):179-82.
• [40]Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y et al.. HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J. 2003; 50(2):173-7.
• [41]Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E, Bartolazzi A, Orlandi F et al.. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch. 2004; 445(2):183-8.
• [42]Guo Z, Hardin H, Montemayor-Garcia C, Asioli S, Righi A, Maletta F, et al. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications. Endocr Pathol. 2015. [Epub ahead of print]
• [43]Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005; 5:29-41.
• [44]Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995; 147:815-22.
• [45]Inohara H, Segawa T, Miyauchi A, Yoshii T, Nakahara S, Raz A et al.. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun. 2008; 376(3):605-10.
• [46]Aiad HA, Kandil MA, Asaad NY, El-Kased AM, El-Goday SF. Galectin-3 immunostaining in cytological and histopathological diagnosis of thyroid lesions. J Egypt Natl Canc Inst. 2008; 20(1):36-46.
• [47]Sapio MR, Guerra A, Posca D, Limone PP, Deandrea M, Motta M et al.. Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer. 2007; 14(4):1089-97.
• [48]Galusca B, Dumollard JM, Lassandre S, Niveleau A, Prades JM, Estour B et al.. Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia. Virchows Arch. 2005; 447(1):18-23.
• [49]Nucera C, Mazzon E, Caillou B, Violi MA, Moleti M, Priolo C et al.. Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia. J Endocrinol Invest. 2005; 28(2):106-12.
• [50]Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol. 2004; 122(4):524-31.
• [51]Torres-Cabala C, Panizo-Santos A, Krutzsch HC, Barazi H, Namba M, Sakaguchi M et al.. Differential expression of S100C in thyroid lesions. Int J Surg Pathol. 2004; 12(2):107-15.
• [52]Lavra L, Rinaldo C, Ulivieri A, Luciani E, Fidanza P, Giacomelli L et al.. The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas. PLoS One. 2011; 6(6):e20665.
• [53]Kovacs RB, Foldes J, Winkler G, Bodo M, Sapi Z. The investigation of galectin-3 in diseases of the thyroid gland. Eur J Endocrinol. 2003; 149(5):449-53.
• [54]Jakubiak-Wielganowicz M, Kubiak R, Sygut J, Pomorski L, Kordek R. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma. Pol J Pathol. 2003; 54(2):111-5.
• [55]Giannini R, Faviana P, Cavinato T, Elisei R, Pacini F, Berti P et al.. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid. 2003; 13(8):765-70.
• [56]Gaffney RL, Carney JA, Sebo TJ, Erickson LA, Volante M, Papotti M et al.. Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland. Am J Surg Pathol. 2003; 27(4):494-8.
• [57]Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab. 2002; 87(10):4806-10.
• [58]Coli A, Bigotti G, Zucchetti F, Negro F, Massi G. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology. 2002; 40(1):80-7.
• [59]Nascimento MC, Bisi H, Alves VA, Longatto-Filho A, Kanamura CT, Medeiros-Neto G. Differential reactivity for galectin-3 in Hurthle cell adenomas and carcinomas. Endocr Pathol. 2001; 12(3):275-9.
• [60]Manivannan P, Siddaraju N, Jatiya L, Verma SK. Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid. Indian J Biochem Biophys. 2012; 49(5):392-4.
• [61]Scarpino S, Di Napoli A, Melotti F, Talerico C, Cancrini A, Ruco L. Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol. 2007; 212(4):411-9.
• [62]El Demellawy D, Nasr AL, Babay S, Alowami S. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathol Res Pract. 2009; 205(5):303-9.
• [63]Park WY, Jeong SM, Lee JH, Kang HJ, Sin DH, Choi KU et al.. Diagnostic value of decreased expression of CD56 protein in papillary carcinoma of the thyroid gland. Basic and Applied Pathology. 2009; 2:63-8.
• [64]Shahebrahimi K, Madani SH, Fazaeli AR, Khazaei S, Kanani M, Keshavarz A. Diagnostic value of CD56 and nm23 markers in papillary thyroid carcinoma. Indian J Pathol Microbiol. 2013; 56(1):2-5.
• [65]Abd El Atti RM, Shash LS. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. J Egypt Natl Canc Inst. 2012; 24(4):175-84.
• [66]Mi KS, Jeong WK, Young SJ. CD56 and high molecular weight cytokeratin as diagnostic markers of papillary thyroid carcinoma. The Korean Journal of Pathology. 2011; 45(5):477-84.
• [67]Etem H, Özekinci S, Mizrak B, Şentürk S. The Role of CD56, HBME-1, and p63 in Follicular Neoplasms of the Thyroid. Turk J Pathol. 2010; 26(3):238-42.
• [68]Satoh F, Umemura S, Yasuda M, Osamura RY. Neuroendocrine marker expression in thyroid epithelial tumors. Endocr Pathol. 2001; 12(3):291-9.
• [69]Nechifor-Boila A, Borda A, Sassolas G, Hafdi-Nejjari Z, Borson-Chazot F, Lifante JC et al.. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56. Pathol Res Pract. 2013; 209(9):585-92.
• [70]Oestreicher-Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R et al.. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck. 2004; 26(11):960-6.